KB-1210

Romosozumab

Background

Romosozumab is a humanized monoclonal antibody used for treating osteoporosis in postmenopausal women who are at a high risk of fracture, as well as in patients who have not responded to other therapies or cannot tolerate them. This medication works by preventing bone resorption and promoting bone formation. However, it is important to note that a study has found an association between Romosozumab and an elevated risk of cardiac death, heart attack, and stroke.

Specifications

Catalog Number:
KB-1210
Cell Line Name:
Romosozumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
SOST
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-420. 2.Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
Please enable JavaScript in your browser to complete this form.